ArticleCells2024
Circulating Exosomal miRNA Profiles in Non-Small Cell Lung Cancers.
Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Clinical significance of miRNAs and exosomal miRNAs in non-small cell lung cancer: diagnostic, prognostic, and therapeutic perspectives.Journal of human genetics · 2026Review
- Urinary Profiles of Exosomal LINE-1 mRNA and Associated miRNAs in Non-Small-Cell Lung Cancer.Cells · 2026Article
- Circulating miR-184 and miR-206 as predictive biomarkers for early recurrence in HBV-related hepatocellular carcinoma: a prospective study.BMC gastroenterology · 2026Article
- Exosomal microRNAs as promising indicators of chemoresistance in lung cancer.Annals of medicine and surgery (2012) · 2026Article
- [Effects of LINC00641 on the Malignant Progression and Chemotherapy Resistance of Non-small Cell Lung Cancer H1299 Cells by Regulating the miR-1306-5p/FGFR3 Axis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- Review
- A circulating microRNA-based diagnostic model for breast cancer, in which the miR-139-3p/RPA2 axis regulates the sensitivity to DNA-damaging agents.Translational cancer research · 2026Article
- Translational insights into miR-126 and miR-423: biomarkers and therapeutic targets in cancer, cardiovascular, metabolic and kidney diseases.Frontiers in molecular biosciences · 2026Review
- Identification of PIWI-interacting RNAs based models for lung adenocarcinoma early detection: a multicenter cohort study.Molecular biomedicine · 2025Article
- Exosomal biomarkers and therapeutics in lung cancer: a narrative review on their role in early detection and targeted treatment.Translational lung cancer research · 2025Review
- Machine learning identifies exosome related gene signatures for early prediction of non-small cell lung cancer.Scientific reports · 2025Article
- Whispers in the Lungs: Small Extracellular Vesicles in Lung Cancer and COPD Crosstalk.Cancers · 2025Review
- Small RNA Landscape of Platelet Dust: Platelet-Derived Extracellular Vesicles from Patients with Non-Small-Cell Lung Cancer.Non-coding RNA · 2025Article
- Recent Exploration of Solid Cancer Biomarkers Hidden Within Urine or Blood Exosomes That Provide Fundamental Information for Future Cancer Diagnostics.Diagnostics (Basel, Switzerland) · 2025Review
- miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease-A New Diagnostic Path?Biomedicines · 2025Article
- Regulatory QTLs affecting miRNA-mRNA interactions in cancer: mechanisms, methods, and clinical implications.Frontiers in molecular biosciences · 2025Review
- Advances in the role of extracellular vesicles in circulating microRNA biomarker discovery for lung cancer.Frontiers in cell and developmental biology · 2025Review
- Exosomal ncRNAs in liquid biopsy: a new paradigm for early cancer diagnosis and monitoring.Frontiers in oncology · 2025Review
- Exosome-Derived miRNAs in Liquid Biopsy for Lung Cancer.Life (Basel, Switzerland) · 2024Review
- Modulation of the Oncogenic LINE-1 Regulatory Network in Non-Small Cell Lung Cancer by Exosomal miRNAs.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A growing number of studies have shown that microRNAs (miRNAs) can exert oncogenic or tumor suppressor activities in a variety of cancers, including lung cancer. Given their presence in exosome preparations, microRNA molecules may in fact participate in exosomal intercellular transfers and signaling. In the present study, we examined the profile of 25 circulating exosomal microRNAs in ostensibly healthy controls compared to patients with squamous cell lung cancers (SQCLC) or lung adenocarcinomas (LUAD). Eight miRNAs, namely, miR-21-5p, miR-126-3p, miR-210-3p, miR-221-3p, Let-7b-5p, miR-146a-5p, miR-222-3p, and miR-9-5p, were highly enriched in the cohort and selected for further analyses. All miRNAs were readily detected in non-small cell lung cancer (NSCLC) patients of both sexes at all cancer stages, and their levels in exosomes correlated with the clinicopathological characteristics of tumors. Thus, the presence of these miRNAs in circulating exosomes may contribute to the regulation of oncogenic activity in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.